Loading clinical trials...
Loading clinical trials...
Immunogenicity and Safety Study of GlaxoSmithKline Biologicals' HPV-16/18 L1 AS04 Vaccine and Merck's Gardasil Vaccine When Administered According to Alternative 2-dose Schedules in 9-14 Year Old Females
Conditions
Interventions
Cervarix
Gardasil
+1 more
Locations
21
France
GSK Investigational Site
Dax, France
GSK Investigational Site
Draguignan, France
GSK Investigational Site
Essey-lès-Nancy, France
GSK Investigational Site
Le Havre, France
GSK Investigational Site
Nice, France
GSK Investigational Site
Paris, France
Start Date
November 21, 2011
Primary Completion Date
October 27, 2015
Completion Date
October 27, 2015
Last Updated
November 15, 2019
NCT01627561
NCT00196937
NCT01190176
NCT01277042
NCT00426361
NCT00345878
Lead Sponsor
GlaxoSmithKline
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions